Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

19.36
Delayed Data
As of Feb 05
 -0.93 / -4.58%
Today’s Change
17.52
Today|||52-Week Range
51.99
-45.69%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.2B

Company Description

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is developing a portfolio consisting of four advanced product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis. It also has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma. ACADIA Pharmaceuticals was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Contact Information

ACADIA Pharmaceuticals, Inc.
3611 Valley Centre Drive
San Diego California 92130-3331
P:(858) 558-2871
Investor Relations:

Employees

Shareholders

Other institutional51.95%
Mutual fund holders49.65%
Individual stakeholders32.53%

Top Executives

Stephen R. DavisPresident, Chief Executive Officer & Director
James A. NashVice President-Technology Development & Operations
Srdjan R. StankovicExecutive VP, Head-Research & Development
James OwenChief Medical Officer & SVP-Clinical Development
Glenn F. BaitySecretary, Executive VP & General Counsel